Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Erlotinib vs Etoposide/Cisplatin With Radiotherapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 TrialInt. J. Radiat. Oncol. Biol. Phys 2020 Nov 18;[EPub Ahead of Print], L Xing, G Wu, L Wang, J Li, J Wang, Z Yuan, M Chen, Y Xu, X Fu, Z Zhu, Y Lu, C Han, T Xia, C Xie, G Li, S Ma, B Lu, Q Lin, G Zhu, B Qu, W Zhu, J Yu
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.